

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC,
Petitioner,

v.

RESEARCH CORPORATION TECHNOLOGIES, INC.,
Patent Owner.

Case No. IPR2016-00204
Patent No. RE38551

**DECLARATION OF WILLIAM R. ROUSH, PH.D.,
IN SUPPORT OF PATENT OWNER RESPONSE
PURSUANT TO 37 C.F.R. § 42.120**

TABLE OF CONTENTS

I.	PRELIMINARY STATEMENT	1
II.	BACKGROUND AND QUALIFICATIONS	2
III.	SUMMARY OF OPINIONS	10
IV.	TECHNICAL BACKGROUND	11
	A. Key Organic Chemistry Principles.....	11
	1. Aromatic and Aliphatic Carbon Molecules	13
	2. Substituted Carbon Molecules	14
	3. Stereochemistry—Racemic Compounds and Enantiomers	16
	4. Amino Acids	26
	B. The Unpredictable Art of Drug Development	27
	1. Biological and Physical Considerations in Drug Development	30
	2. Lead Compound Identification	36
	3. The Difficulty of Predicting Effects of Structural Changes	37
V.	THE '551 PATENT	46
	A. Overview	46
	B. Claims of the '551 Patent	50
	1. Claims 1-9	50
	2. Claim 10	51
	3. Claims 11-13	51
	C. Level of Ordinary Skill in the Art	52
	D. The Board's Claim Construction.....	54
VI.	STATE OF THE PRIOR ART	54
	A. Judith D. Conley & Harold Kohn, Functionalized DL-Amino Acid Derivatives. Potent New Agents for the Treatment of Epilepsy, 30 J. Med. Chem. 567 (1987) (Exhibit 2004) ("Conley 1987")	55
	1. The results of modifications at the α -carbon.	59
	2. The results of modifications at the N-benzylamide.....	62
	3. The results of modifications at the N-acetyl.....	64

B.	Harold Kohn et al., Marked Stereospecificity in a New Class of Anticonvulsants, 457 Brain Res. 371 (1988) (Exhibit 2053) (“Kohn 1988”).....	65
C.	Harold Kohn et al., Preparation and Anticonvulsant Activity of a Series of Functionalized α -Aromatic and α -Heteroaromatic Amino Acids, 33 J. Med. Chem. 919 (1990) (Exhibit 1018) (“Kohn 1990”).....	67
D.	Harold Kohn et al., Preparation and Anticonvulsant Activity of a Series of Functionalized α -Heteroatom-Substituted Amino Acids, 34 J. Med. Chem. 2444 (1991) (Exhibit 1012) (“Kohn 1991”).....	71
E.	U.S. Patent No. 5,378,729 (Exhibit 1009) (“the ’729 patent”).....	77
F.	Harold Kohn et al., Synthesis and Anticonvulsant Activities of α -Heterocyclic α -Acetamido-N-Benzylacetamide Derivatives, 36 J. Med. Chem. 3350 (1993) (Exhibit 1017) (“Kohn 1993”).....	80
G.	Harold Kohn et al., Anticonvulsant Properties of N-Substituted α,α -Diamino Acid Derivatives, 83 J. Pharmaceutical Sci. 689 (May 1994) (Exhibit 2055) (“Kohn 1994”).....	88
H.	Patrick Bardel et al., Synthesis and Anticonvulsant Activities of α -Acetamido-N Benzylacetamide Derivatives Containing an Electron-Deficient α -Heteroaromatic Substituent, 37 J. Med. Chem. 4567 (1994) (Exhibit 2056) (“Bardel 1994”).....	90
I.	Silverman, R. B., <i>The Organic Chemistry of Drug Design and Drug Action</i> , Academic Press (1992) (Exhibit 1013) (“Silverman”).....	93
VII.	A POSA WOULD NOT HAVE SELECTED A FUNCTIONALIZED AMINO ACID AS A LEAD COMPOUND WHEN SEARCHING FOR A NEW ANTI-EPILEPTIC DRUG.....	96
A.	No FAA Compound Had Been Approved by the FDA.	96
B.	No FAA Compound Was Included in Cumulative Reviews of Potentially Promising AEDs.	101
C.	The Mode of Action and Target of FAAs in Preventing Seizures Was Not Understood.....	102
D.	There Was Not Yet Enough Data for a POSA to Have a Reasonable Understanding of FAA Properties, Let Alone SAR.	103
VIII.	A POSA WOULD NOT HAVE SELECTED THE METHOXYAMINO COMPOUND 31 AS A LEAD COMPOUND.....	107

A.	The State of the Art as of March 1996.....	107
1.	Identifying potential AED candidates was challenging and highly unpredictable.....	107
2.	The state of the art demonstrated that the SAR of the numerous areas for modification on the FAA backbone was not sufficiently advanced to draw reasonable expectations about each modification’s biological impact....	108
B.	Even Assuming a POSA Would Select an FAA as a Lead Compound, a POSA Would Not Have Selected the Methoxyamino Compound (Kohn 1991 Compound 3l) as a Lead Compound.	130
IX.	EVEN ASSUMING, <i>ARGUENDO</i> , THAT A POSA WOULD SELECT AN FAA AS A LEAD COMPOUND, AND WOULD HAVE SELECTED THE METHOXYAMINO COMPOUND (KOHN 1991 COMPOUND 3L) AS A LEAD COMPOUND, A POSA WOULD NOT HAVE MODIFIED COMPOUND 3L INTO THE COMPOUNDS OF CLAIMS 1-9 WITH A REASONABLE EXPECTATION OF SUCCESS.	135
X.	CLAIMS 10-13.....	154
XI.	UNEXPECTED RESULTS.....	156
XII.	LONG FELT NEED/FAILURE OF OTHERS	160
XIII.	SKEPTICISM.....	163
XIV.	CONCLUSION.....	164

I. PRELIMINARY STATEMENT

I, WILLIAM R. ROUSH, Ph.D., hereby state as follows:

1. I have been retained as a consultant on behalf of Research Corporation Technologies, Inc. (“RCT”), the patent owner in the present proceeding. I understand that the petition names Argentum Pharmaceuticals LLC (“Argentum”) as the petitioner, and that Intelligent Pharma Research LLC, APS GP LLC, and APS GP Investors LLC have been identified as real parties-in-interest. I further understand that KVK-TECH, Inc. has also been identified as a potential real party-in-interest. I have no financial interest in, or affiliation with, the petitioner, the identified actual or potential real parties-in-interest, or the patent owner. I am being compensated for my work at my usual and customary consulting rate, and my compensation is not dependent upon the outcome of, or my testimony in, the present *inter partes* review or any litigation proceedings.

2. I have reviewed the Petition for *Inter Partes* Review of Patent No. RE38,551 (“the ’551 Patent”) filed by Argentum Pharmaceuticals LLC, including Dr. Wang’s Declaration, as well as the exhibits and articles cited in those documents. I have also reviewed the articles and documents cited in this declaration.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.